Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility.

Zhang S, Shi W, Ramsay ES, Bliskovsky V, Eiden AM, Connors D, Steinsaltz M, DuBois W, Mock BA.

J Biol Chem. 2019 Sep 23. pii: jbc.RA119.009779. doi: 10.1074/jbc.RA119.009779. [Epub ahead of print]

2.

The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription.

Malik N, Yan H, Moshkovich N, Palangat M, Yang H, Sanchez V, Cai Z, Peat TJ, Jiang S, Liu C, Lee M, Mock BA, Yuspa SH, Larson D, Wakefield LM, Huang J.

Nat Commun. 2019 May 6;10(1):2071. doi: 10.1038/s41467-019-10102-6.

3.

Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex.

Calabrese DR, Chen X, Leon EC, Gaikwad SM, Phyo Z, Hewitt WM, Alden S, Hilimire TA, He F, Michalowski AM, Simmons JK, Saunders LB, Zhang S, Connors D, Walters KJ, Mock BA, Schneekloth JS Jr.

Nat Commun. 2018 Oct 12;9(1):4229. doi: 10.1038/s41467-018-06315-w.

4.

Characterization of clinically used oral antiseptics as quadruplex-binding ligands.

Calabrese DR, Zlotkowski K, Alden S, Hewitt WM, Connelly CM, Wilson RM, Gaikwad S, Chen L, Guha R, Thomas CJ, Mock BA, Schneekloth JS Jr.

Nucleic Acids Res. 2018 Apr 6;46(6):2722-2732. doi: 10.1093/nar/gky084.

5.

The Reign of Antibodies: A Celebration of and Tribute to Michael Potter and His Homogeneous Immunoglobulin Workshops.

Gearhart PJ, Mock BA, Casellas R, Cancro MP.

J Immunol. 2018 Jan 1;200(1):23-26. doi: 10.4049/jimmunol.1701516. No abstract available.

6.

mTOR intersects antibody-inducing signals from TACI in marginal zone B cells.

Sintes J, Gentile M, Zhang S, Garcia-Carmona Y, Magri G, Cassis L, Segura-Garzón D, Ciociola A, Grasset EK, Bascones S, Comerma L, Pybus M, Lligé D, Puga I, Gutzeit C, He B, DuBois W, Crespo M, Pascual J, Mensa A, Aróstegui JI, Juan M, Yagüe J, Serrano S, Lloreta J, Meffre E, Hahne M, Cunningham-Rundles C, Mock BA, Cerutti A.

Nat Commun. 2017 Nov 13;8(1):1462. doi: 10.1038/s41467-017-01602-4.

7.

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, Zhang K, Gary J, Zhang S, Gaikwad S, Connors D, Watson N, Leon E, Chen JQ, Kuehl WM, Lee MP, Zingone A, Landgren O, Ordentlich P, Huang J, Mock BA.

Mol Cancer Ther. 2017 Sep;16(9):2008-2021. doi: 10.1158/1535-7163.MCT-17-0171. Epub 2017 May 18.

8.

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.

Eiden AM, Zhang S, Gary JM, Simmons JK, Mock BA.

Clin Cancer Res. 2016 Jan 15;22(2):277-83. doi: 10.1158/1078-0432.CCR-14-3239. Epub 2015 Nov 25. Review.

9.

Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.

Felsenstein KM, Saunders LB, Simmons JK, Leon E, Calabrese DR, Zhang S, Michalowski A, Gareiss P, Mock BA, Schneekloth JS Jr.

ACS Chem Biol. 2016 Jan 15;11(1):139-48. doi: 10.1021/acschembio.5b00577. Epub 2015 Nov 6.

10.

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.

Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ.

Cancer Lett. 2014 Nov 28;354(2):336-47. doi: 10.1016/j.canlet.2014.08.043. Epub 2014 Sep 1.

11.

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.

Mol Oncol. 2014 Mar;8(2):261-72. doi: 10.1016/j.molonc.2013.11.007. Epub 2013 Dec 3.

12.

B cell-specific deficiencies in mTOR limit humoral immune responses.

Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA.

J Immunol. 2013 Aug 15;191(4):1692-703. doi: 10.4049/jimmunol.1201767. Epub 2013 Jul 15.

13.

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Smrž D, Bandara G, Zhang S, Mock BA, Beaven MA, Metcalfe DD, Gilfillan AM.

J Immunol Methods. 2013 Apr 30;390(1-2):52-62. doi: 10.1016/j.jim.2013.01.008. Epub 2013 Jan 25.

14.

Mouse genetics 2011: meeting report.

Simmons JK, Amlin-Van Schaick JC, Geiger TR, Reilly K, Hunter K, Mock BA.

Mamm Genome. 2012 Apr;23(3-4):225-31. doi: 10.1007/s00335-012-9390-6. Epub 2012 Feb 23. No abstract available.

15.

mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.

Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD, Gilfillan AM.

Blood. 2011 Dec 22;118(26):6803-13. doi: 10.1182/blood-2011-06-359984. Epub 2011 Nov 3.

16.

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA.

Blood. 2011 Jan 27;117(4):1228-38. doi: 10.1182/blood-2010-05-287821. Epub 2010 Nov 15.

17.

Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.

Zhang K, Kagan D, DuBois W, Robinson R, Bliskovsky V, Vass WC, Zhang S, Mock BA.

Blood. 2009 Oct 1;114(14):2952-60. doi: 10.1182/blood-2009-01-198812. Epub 2009 Aug 4.

18.

The Collaborative Cross, a community resource for the genetic analysis of complex traits.

Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, Berrettini W, Bleich A, Bogue M, Broman KW, Buck KJ, Buckler E, Burmeister M, Chesler EJ, Cheverud JM, Clapcote S, Cook MN, Cox RD, Crabbe JC, Crusio WE, Darvasi A, Deschepper CF, Doerge RW, Farber CR, Forejt J, Gaile D, Garlow SJ, Geiger H, Gershenfeld H, Gordon T, Gu J, Gu W, de Haan G, Hayes NL, Heller C, Himmelbauer H, Hitzemann R, Hunter K, Hsu HC, Iraqi FA, Ivandic B, Jacob HJ, Jansen RC, Jepsen KJ, Johnson DK, Johnson TE, Kempermann G, Kendziorski C, Kotb M, Kooy RF, Llamas B, Lammert F, Lassalle JM, Lowenstein PR, Lu L, Lusis A, Manly KF, Marcucio R, Matthews D, Medrano JF, Miller DR, Mittleman G, Mock BA, Mogil JS, Montagutelli X, Morahan G, Morris DG, Mott R, Nadeau JH, Nagase H, Nowakowski RS, O'Hara BF, Osadchuk AV, Page GP, Paigen B, Paigen K, Palmer AA, Pan HJ, Peltonen-Palotie L, Peirce J, Pomp D, Pravenec M, Prows DR, Qi Z, Reeves RH, Roder J, Rosen GD, Schadt EE, Schalkwyk LC, Seltzer Z, Shimomura K, Shou S, Sillanpää MJ, Siracusa LD, Snoeck HW, Spearow JL, Svenson K, Tarantino LM, Threadgill D, Toth LA, Valdar W, de Villena FP, Warden C, Whatley S, Williams RW, Wiltshire T, Yi N, Zhang D, Zhang M, Zou F; Complex Trait Consortium.

Nat Genet. 2004 Nov;36(11):1133-7.

PMID:
15514660
19.

The nature and identification of quantitative trait loci: a community's view.

Abiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, Bennett B, Blankenhorn EP, Blizard DA, Bolivar V, Brockmann GA, Buck KJ, Bureau JF, Casley WL, Chesler EJ, Cheverud JM, Churchill GA, Cook M, Crabbe JC, Crusio WE, Darvasi A, de Haan G, Dermant P, Doerge RW, Elliot RW, Farber CR, Flaherty L, Flint J, Gershenfeld H, Gibson JP, Gu J, Gu W, Himmelbauer H, Hitzemann R, Hsu HC, Hunter K, Iraqi FF, Jansen RC, Johnson TE, Jones BC, Kempermann G, Lammert F, Lu L, Manly KF, Matthews DB, Medrano JF, Mehrabian M, Mittlemann G, Mock BA, Mogil JS, Montagutelli X, Morahan G, Mountz JD, Nagase H, Nowakowski RS, O'Hara BF, Osadchuk AV, Paigen B, Palmer AA, Peirce JL, Pomp D, Rosemann M, Rosen GD, Schalkwyk LC, Seltzer Z, Settle S, Shimomura K, Shou S, Sikela JM, Siracusa LD, Spearow JL, Teuscher C, Threadgill DW, Toth LA, Toye AA, Vadasz C, Van Zant G, Wakeland E, Williams RW, Zhang HG, Zou F; Complex Trait Consortium.

Nat Rev Genet. 2003 Nov;4(11):911-6. Review.

20.

Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.

Bliskovsky V, Ramsay ES, Scott J, DuBois W, Shi W, Zhang S, Qian X, Lowy DR, Mock BA.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14982-7. Epub 2003 Nov 21.

21.

p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB.

Zhang S, Qian X, Redman C, Bliskovski V, Ramsay ES, Lowy DR, Mock BA.

Oncogene. 2003 Apr 17;22(15):2285-95.

PMID:
12700664
22.

Might wasp venom desensitization induced Th2 to Th1 shift cause pregnancy failure?

Markert UR, Arck PC, Peiker G, Mock BA.

Am J Reprod Immunol. 2002 Apr;47(4):193-5.

PMID:
12069385
23.

Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility.

Zhang SL, DuBois W, Ramsay ES, Bliskovski V, Morse HC 3rd, Taddesse-Heath L, Vass WC, DePinho RA, Mock BA.

Mol Cell Biol. 2001 Jan;21(1):310-8.

24.

[Specific immunotherapy (hyposensitization) with insect venom in pregnancy].

Mock BA, Peiker G, Markert UR, Jäger L.

Z Geburtshilfe Neonatol. 2000 May-Jun;204(3):117-9. German.

PMID:
10909168
25.

Structure and localization of mouse Pmscl1 and Pmscl2 genes.

Bliskovski V, Liddell R, Ramsay ES, Miller MJ, Mock BA.

Genomics. 2000 Feb 15;64(1):106-10.

PMID:
10708524
26.

Mapping of the SWAP70 gene to mouse chromosome 7 and human chromosome 11p15.

Masat L, Liddell RA, Mock BA, Kuo WL, Jessberger R, Wabl M, Morse HC 3rd.

Immunogenetics. 2000 Jan;51(1):16-9.

PMID:
10663557
27.

Mouse chromosome 4.

Liddell RA, Hirano MC, Mock BA.

Mamm Genome. 1999 Oct;10(10):943. No abstract available.

PMID:
10501946
28.

The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors.

Zhang S, Mock BA.

Curr Top Microbiol Immunol. 1999;246:363-7; discussion 368. No abstract available.

PMID:
10396076
29.

Multigenic control of skin tumor susceptibility in SENCARA/Pt mice.

Mock BA, Lowry DT, Rehman I, Padlan C, Yuspa SH, Hennings H.

Carcinogenesis. 1998 Jun;19(6):1109-15.

PMID:
9667751
30.

Encyclopedia of the mouse genome VII. Mouse chromosome 4.

Mock BA, Hirano MC.

Mamm Genome. 1998;8 Spec No:S68-90. No abstract available.

PMID:
9662621
31.
32.

Gene organization and chromosome location of the neural-specific RNA binding protein Elavl4.

Inman MV, Levy S, Mock BA, Owens GC.

Gene. 1998 Feb 27;208(2):139-45.

PMID:
9524251
33.

The plasmacytoma resistance gene, Pctr2, delays the onset of tumorigenesis and resides in the telomeric region of chromosome 4.

Mock BA, Hartley J, Le Tissier P, Wax JS, Potter M.

Blood. 1997 Nov 15;90(10):4092-8.

PMID:
9354679
34.

Mouse chromosome 4.

Mock BA, Neumann PE, Fiedorek FT Jr.

Mamm Genome. 1997;7 Spec No:S60-79. No abstract available.

PMID:
9233387
36.

Riz maps to distal chromosome 4 near genes involved in tumorigenesis and nerve degeneration.

Mock BA, Coleman MP, Huang S.

Mamm Genome. 1996 Aug;7(8):637. No abstract available.

PMID:
8679000
37.

Plasmacytoma-associated neuronal glycoprotein, Pang, maps to mouse chromosome 6 and human chromosome 3.

Mock BA, Connelly MA, McBride OW, Kozak CA, Marcu KB.

Genomics. 1996 Jun 1;34(2):226-8.

PMID:
8661054
38.

Molecular cloning, chromosomal mapping, and expression of the mouse p107 gene.

Huppi K, Siwarski D, Mock BA, Dosik J, Hamel PA.

Mamm Genome. 1996 May;7(5):353-5.

PMID:
8661722
39.

Encyclopedia of the mouse genome V. Mouse chromosome 4.

Mock BA, Stoye J, Spence J, Jackson I, Eppig JT, Fiedorek FT Jr, Neumann PE.

Mamm Genome. 1996;6 Spec No:S73-96. No abstract available.

PMID:
8800780
40.

Encyclopedia of the mouse genome V. Mouse chromosome 15.

Huppi K, Siwarski D, Eppig JT, Mock BA.

Mamm Genome. 1996;6 Spec No:S256-70. No abstract available.

PMID:
8800770
41.

Interleukin 6 is essential for in vivo development of B lineage neoplasms.

Hilbert DM, Kopf M, Mock BA, Köhler G, Rudikoff S.

J Exp Med. 1995 Jul 1;182(1):243-8.

42.

CHUK, a conserved helix-loop-helix ubiquitous kinase, maps to human chromosome 10 and mouse chromosome 19.

Mock BA, Connelly MA, McBride OW, Kozak CA, Marcu KB.

Genomics. 1995 May 20;27(2):348-51.

PMID:
7558004
43.

Nonrandom chromosomal change (trisomy 11) in murine plasmacytomas induced by an ABL-MYC retrovirus.

Wiener F, Coleman A, Mock BA, Potter M.

Cancer Res. 1995 Mar 1;55(5):1181-8.

44.

Genetic regulation of leishmanial and mycobacterial infections: the Lsh/Ity/Bcg gene story continues.

Blackwell JM, Barton CH, White JK, Roach TI, Shaw MA, Whitehead SH, Mock BA, Searle S, Williams H, Baker AM.

Immunol Lett. 1994 Dec;43(1-2):99-107. Review.

PMID:
7737696
45.

Genetic and physical mapping of 2q35 in the region of the NRAMP and IL8R genes: identification of a polymorphic repeat in exon 2 of NRAMP.

White JK, Shaw MA, Barton CH, Cerretti DP, Williams H, Mock BA, Carter NP, Peacock CS, Blackwell JM.

Genomics. 1994 Nov 15;24(2):295-302.

PMID:
7698752
46.
47.

The inducible form of nitric oxide synthase (NOS2) isolated from murine macrophages maps near the nude mutation on mouse chromosome 11.

Mock BA, Krall MM, Byrd LG, Chin H, Barton CH, Charles I, Liew FY, Blackwell J.

Eur J Immunogenet. 1994 Aug;21(4):231-8.

PMID:
9098436
48.

An Nramp-related sequence maps to mouse chromosome 17.

Dosik JK, Barton CH, Holiday DL, Krall MM, Blackwell JM, Mock BA.

Mamm Genome. 1994 Jul;5(7):458-60. No abstract available.

PMID:
7919662
49.

The gene for mouse p58cdc2L1 (Cdc2l1) protein kinase maps to distal mouse chromosome 4.

Mock BA, Padlan C, Kozak CA, Kidd V.

Mamm Genome. 1994 Mar;5(3):191-2. No abstract available.

PMID:
8199413
50.

Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice.

Potter M, Mushinski EB, Wax JS, Hartley J, Mock BA.

Cancer Res. 1994 Feb 15;54(4):969-75.

PMID:
8313388

Supplemental Content

Support Center